FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883461158> ?p ?o ?g. }

• W2883461158 endingPage "131" @default.
• W2883461158 startingPage "123" @default.
• W2883461158 abstract "Background: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms. Objective: We sought to determine the survival benefits that clinical investigators would judge as sufficient to warrant treatment with adjuvant sorafenib in the SORCE trial after nephrectomy for apparently localised renal cell carcinoma (RCC). Methods: A subset of clinical investigators in the SORCE trial completed a validated questionnaire that elicited the minimum survival benefits they judged sufficient to warrant one year of adjuvant sorafenib in scenarios with hypothetical baseline survival times of 5 years and 15 years, and baseline survival rates at 5 years of 65% and 85%. Results: The 100 participating SORCE investigators had a median age of 42 years, and 74 were male. For one year of sorafenib versus no therapy, the median benefits in survival times the investigators judged sufficient to warrant treatment were an extra nine months beyond five years and an extra 12 months beyond 15 years; the median benefits in survival rates were an extra 5% beyond baseline survival rates of both 65% and 85% at five years. The patients recruited in the SORCE trial by these investigators judged smaller benefits sufficient to warrant adjuvant sorafenib for both survival rate scenarios (p≤0.0001). The survival benefits the investigators judged sufficient to warrant one year of adjuvant therapy with sorafenib for RCC were similar to those of other clinicians considering three months of adjuvant chemotherapy for lung cancer, but smaller than those of clinicians considering six months of adjuvant chemotherapy for breast cancer. Conclusion: SORCE investigators judged larger benefits necessary to warrant adjuvant sorafenib than their patients. The benefits required by the investigators were similar or smaller than those other clinicians considered sufficient to warrant adjuvant chemotherapy for other cancers. Clinicians should recognise that their patients and colleagues may have preferences that differ from their own when considering the potential benefits and harms of adjuvant treatment." @default.
• W2883461158 created "2018-08-03" @default.
• W2883461158 creator A5009931700 @default.
• W2883461158 creator A5018620241 @default.
• W2883461158 creator A5024778370 @default.
• W2883461158 creator A5031626579 @default.
• W2883461158 creator A5033091020 @default.
• W2883461158 creator A5036001957 @default.
• W2883461158 creator A5041574043 @default.
• W2883461158 creator A5048383561 @default.
• W2883461158 creator A5051230731 @default.
• W2883461158 creator A5058223039 @default.
• W2883461158 creator A5061757629 @default.
• W2883461158 creator A5064732405 @default.
• W2883461158 creator A5068552855 @default.
• W2883461158 creator A5072953177 @default.
• W2883461158 date "2018-08-01" @default.
• W2883461158 modified "2023-10-18" @default.
• W2883461158 title "What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial" @default.
• W2883461158 cites W1821273786 @default.
• W2883461158 cites W1996210830 @default.
• W2883461158 cites W1999966467 @default.
• W2883461158 cites W2047301850 @default.
• W2883461158 cites W2062883742 @default.
• W2883461158 cites W2069480574 @default.
• W2883461158 cites W2080983682 @default.
• W2883461158 cites W2086616704 @default.
• W2883461158 cites W2093944201 @default.
• W2883461158 cites W2100695330 @default.
• W2883461158 cites W2112733638 @default.
• W2883461158 cites W2133157945 @default.
• W2883461158 cites W2149456801 @default.
• W2883461158 cites W2161932461 @default.
• W2883461158 cites W2276173793 @default.
• W2883461158 cites W2293077587 @default.
• W2883461158 cites W2530419161 @default.
• W2883461158 cites W2536284959 @default.
• W2883461158 cites W2734451381 @default.
• W2883461158 cites W2756219586 @default.
• W2883461158 cites W2768552367 @default.
• W2883461158 doi "https://doi.org/10.3233/kca-180038" @default.
• W2883461158 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6364092" @default.
• W2883461158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30740581" @default.
• W2883461158 hasPublicationYear "2018" @default.
• W2883461158 type Work @default.
• W2883461158 sameAs 2883461158 @default.
• W2883461158 citedByCount "4" @default.
• W2883461158 countsByYear W28834611582019 @default.
• W2883461158 countsByYear W28834611582020 @default.
• W2883461158 countsByYear W28834611582022 @default.
• W2883461158 crossrefType "journal-article" @default.
• W2883461158 hasAuthorship W2883461158A5009931700 @default.
• W2883461158 hasAuthorship W2883461158A5018620241 @default.
• W2883461158 hasAuthorship W2883461158A5024778370 @default.
• W2883461158 hasAuthorship W2883461158A5031626579 @default.
• W2883461158 hasAuthorship W2883461158A5033091020 @default.
• W2883461158 hasAuthorship W2883461158A5036001957 @default.
• W2883461158 hasAuthorship W2883461158A5041574043 @default.
• W2883461158 hasAuthorship W2883461158A5048383561 @default.
• W2883461158 hasAuthorship W2883461158A5051230731 @default.
• W2883461158 hasAuthorship W2883461158A5058223039 @default.
• W2883461158 hasAuthorship W2883461158A5061757629 @default.
• W2883461158 hasAuthorship W2883461158A5064732405 @default.
• W2883461158 hasAuthorship W2883461158A5068552855 @default.
• W2883461158 hasAuthorship W2883461158A5072953177 @default.
• W2883461158 hasBestOaLocation W28834611581 @default.
• W2883461158 hasConcept C10138342 @default.
• W2883461158 hasConcept C111368507 @default.
• W2883461158 hasConcept C126322002 @default.
• W2883461158 hasConcept C12725497 @default.
• W2883461158 hasConcept C127313418 @default.
• W2883461158 hasConcept C143998085 @default.
• W2883461158 hasConcept C162324750 @default.
• W2883461158 hasConcept C2776916960 @default.
• W2883461158 hasConcept C2777472916 @default.
• W2883461158 hasConcept C2777863537 @default.
• W2883461158 hasConcept C2778019345 @default.
• W2883461158 hasConcept C2778695046 @default.
• W2883461158 hasConcept C535046627 @default.
• W2883461158 hasConcept C71924100 @default.
• W2883461158 hasConceptScore W2883461158C10138342 @default.
• W2883461158 hasConceptScore W2883461158C111368507 @default.
• W2883461158 hasConceptScore W2883461158C126322002 @default.
• W2883461158 hasConceptScore W2883461158C12725497 @default.
• W2883461158 hasConceptScore W2883461158C127313418 @default.
• W2883461158 hasConceptScore W2883461158C143998085 @default.
• W2883461158 hasConceptScore W2883461158C162324750 @default.
• W2883461158 hasConceptScore W2883461158C2776916960 @default.
• W2883461158 hasConceptScore W2883461158C2777472916 @default.
• W2883461158 hasConceptScore W2883461158C2777863537 @default.
• W2883461158 hasConceptScore W2883461158C2778019345 @default.
• W2883461158 hasConceptScore W2883461158C2778695046 @default.
• W2883461158 hasConceptScore W2883461158C535046627 @default.
• W2883461158 hasConceptScore W2883461158C71924100 @default.
• W2883461158 hasIssue "2" @default.
• W2883461158 hasLocation W28834611581 @default.
• W2883461158 hasLocation W28834611582 @default.
• W2883461158 hasLocation W28834611583 @default.

• next